Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Alfacalcidol for steroid-associated bone disease and urinary protein in pediatric nephrotic syndrome
ChiCTR2200055790Phase 4Recruiting
- Sponsor
- Guangzhou Women and Children's Medical Center
- Start
- Mar 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, single-blind trial of alfacalcidol in nephrosis, glucocorticoid-induced osteoporosis (GIOP) and bone disease (2 arms), sponsored by Guangzhou Women and Children's Medical Center. Primary endpoints: Bone mineral density and Cumulative dose of glucocorticoid. Started Mar 2022; status: recruiting.
02
Drugs
alfacalcidol
03
Conditions
nephrosisglucocorticoid-induced osteoporosis (GIOP)bone disease
Beyond the preview
Go deeper on ChiCTR2200055790.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2200055790.